Clinical trialsCompany release

CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer

🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026

Topline data show a recurrence-free survival hazard ratio of 0.32 with no Grade 3 or higher treatment-related adverse events, and the company is widening its planned BLA filings.

CG Oncology reported on 16 November 2026 that its Phase 3 PIVOT-006 trial met its primary endpoint. The study tested adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC) and in those with high-grade Ta disease.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CG Oncology, Inc. ↗

Article written by VigiEye from the official source (CG Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →